Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417237 | 0.87 | KMT2A (0.44) | CYP2C9CYP2C19PTGS1PTGS2MEN1 | |
| SCHEMBL5404020 | 0.84 | LTA4H (0.44) | PTGS1PTGS2CACNA1BKMT2AALDH1A1 | |
| SCHEMBL5392936 | 0.81 | KMT2A (0.41) | KCNA5CACNA1BMEN1KMT2ANPY1R | |
| SCHEMBL5392572 | 0.80 | LTA4H (0.50) | PTGS1PTGS2KCNA5MEN1KMT2A | |
| SCHEMBL5406376 | 0.79 | MAPT (0.43) | PTGS1PTGS2KCNA5NPY1R | |
| SCHEMBL5402972 | 0.79 | ACHE (0.43) | CYP2D6PTGS1PTGS2KMT2ANPY1R | |
| SCHEMBL5402531 | 0.79 | LTA4H (0.45) | PTGS1PTGS2NPY1R | |
| SCHEMBL5418655 | 0.79 | PTGS1 (0.51) | PTGS1PTGS2KCNA5SMN1; SMN2MEN1 | |
| SCHEMBL5398626 | 0.78 | KCNH2 (0.42) | KCNA5CACNA1BMEN1KMT2AALDH1A1 | |
| SCHEMBL5407260 | 0.78 | CACNA1B (0.49) | PTGS1PTGS2CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | disclosed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | disclosed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | disclosed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | disclosed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | CACNA1S, CACNA1I, CACNA1C | CYP1A2 1236/4885CYP3A4 2451/4885CYP2D6 400/4885 |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | CACNA1S, CACNA1I, NLN | CYP1A2 1316/4885CYP3A4 2349/4885CYP2D6 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.